The authors proposed that IER5 can competitively bind to a Cdc25B promoter transcription factor-binding site in myeloid leukemia cells, thereby releasing transcription factors, such as NF-YB and p300, and inhibiting transcription. Here, IER5 is linked to myeloid leukemia.